MEI PHARMA
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myelo... id leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.
MEI PHARMA
Social Links:
Industry:
Biopharma Biotechnology Medical
Founded:
2000-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.meipharma.com
Total Employee:
11+
Status:
Active
Contact:
858-792-6300
Email Addresses:
[email protected]
Total Funding:
160.36 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Google Tag Manager Content Delivery Network Font Awesome Global Site Tag Mobile Non Scaleable Content
Similar Organizations
Ansun BioPharma
Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of host-directed anti-viral.
Lineage Cell Therapeutics
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Stock Details
Investors List
CAM Capital
CAM Capital investment in Post-IPO Equity - MEI Pharma
Vivo Capital
Vivo Capital investment in Post-IPO Equity - MEI Pharma
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - MEI Pharma
Biotechnology Value Fund
Biotechnology Value Fund investment in Post-IPO Equity - MEI Pharma
Perceptive Advisors
Perceptive Advisors investment in Post-IPO Equity - MEI Pharma
Boxer Capital
Boxer Capital investment in Post-IPO Equity - MEI Pharma
Amzak Health Investors
Amzak Health Investors investment in Post-IPO Equity - MEI Pharma
3B Future Health Fund
3B Future Health Fund investment in Post-IPO Equity - MEI Pharma
RA Capital Management
RA Capital Management investment in Post-IPO Equity - MEI Pharma
Vivo Capital
Vivo Capital investment in Post-IPO Equity - MEI Pharma
Key Employee Changes
Official Site Inspections
http://www.meipharma.com Semrush global rank: 2.03 M Semrush visits lastest month: 10.38 K
- Host name: 172.67.170.215
- IP address: 172.67.170.215
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "MEI Pharma"
About MEI Pharma | MEI Pharma
We are a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. Our approach to oncology drug development is to evaluate our drug …See details»
MEI Pharma, Inc. (MEIP) Company Profile & Facts - Yahoo Finance
See the company profile for MEI Pharma, Inc. (MEIP) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
MEI Pharma (MEIP) Company Profile & Description - Stock Analysis
Dec 19, 2003 Company profile for MEI Pharma, Inc. (MEIP) stock, with a description, list of executives, contact details and other key facts.See details»
MEI Pharma Company Profile | Management and Employees List
Find contact information for MEI Pharma. Learn about their Research & Development, Business Services market share, competitors, and MEI Pharma's email format.See details»
MEI Pharma, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
May 7, 2025 The drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 inhibitor. For more information, please visit www.meipharma.com. Follow us on X (formerly …See details»
MEI Pharma - Crunchbase Company Profile & Funding
MEI Pharma is a oncology company focuses on the clinical development of novel therapies for cancer.See details»
MEI Pharma Inc Company Profile - Overview - GlobalData
MEI Pharma Inc (MEI Pharma) is a pharmaceutical company. It is focused on developing innovative therapies for cancer. The company's pipeline includes Voruciclib, an oral CDK9 …See details»
Homepage | MEI Pharma
Jul 18, 2025 HomepageOncology Focused, Patient Centric We are committed to the development of novel and differentiated cancer therapies intended to overcome known drug resistance mechanisms in combination with standard-of …See details»
MEI Pharma Initiates Strategic Realignment - Business Wire
Dec 5, 2022 Strategic Realignment Overview MEIP plans to streamline its organization towards the continued clinical development of voruciclib and ME-344.See details»
MEI Pharma (LON:0JW9) Company Profile & Description
May 15, 2025 Company profile for MEI Pharma, Inc. (LON:0JW9) with a description, list of executives, contact details and other key facts.See details»
MEI Pharma Announces $100,000,000 Private Placement to Initiate ...
Jul 18, 2025 MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National ExchangeSee details»
MEI Pharma 2023 Annual Report
Previosly, he served as Chief Medical Officer of Seattle Genetics from March 2007 until his retirement in February 2013. While at Seattle Genetics, he was responsible for building and …See details»
MEI Pharma Acquires Litecoin, Launches $100M Institutional …
2 days ago For more information, please visit www.meipharma.com. Follow us on X (formerly Twitter) @MEI_Pharma and on LinkedIn. Forward-Looking StatementsSee details»
MEI Pharma Initiates Strategic Realignment
Dec 5, 2022 Initiate a Phase 1b study evaluating ME-344 plus Avastin® (bevacizumab) in relapsed colorectal cancer patients in the first half of calendar year 2023. Strategic …See details»
Investor Summary | MEI Pharma
Jul 30, 2025 The Investor Relations website contains information about MEI Pharma's business for stockholders, potential investors, and financial analysts.See details»
Careers - MEI Pharma
Careers | MEI PharmaPaid Time Off 12 Holidays Per Year Five Sick Days Summer Hours Hybrid Work Option Volunteer Time Off Equal Opportunity Employer: MEI Pharma, Inc.'s policy is to …See details»
MEI Pharma 2023 Annual Report
Essential elements of our Human Capital efforts concern workforce planning, talent acquisition, diversity, equity & inclusion, and workforce optimization the ongoing development of our …See details»
MEI Pharma to Release 2022 Fiscal Year End Financial Results and ...
Sep 1, 2022 SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today …See details»
Our Focus - MEI Pharma
Our Focus | MEI PharmaWe strive to develop novel and differentiated cancer therapies in combinations with standard-of-care therapies to overcome known resistance mechanisms and …See details»
MEI Pharma Acquires Litecoin, Launches $100M Institutional …
3 days ago MEI Pharma (Nasdaq: MEIP) is a pharmaceutical company with a portfolio of several drug candidates that may offer novel and differentiated therapies. Its treasury initiative — …See details»